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Abstract
We identified a small colony variant (SCV) of an amoxicillin/clavulanic acid- resistant derivative of a clinical isolate of Escherichia 
coli from Malawi, which was selected for in vitro in a subinhibitory concentration of gentamicin. The SCV was auxotrophic for 
hemin and had impaired biofilm formation compared to the ancestral isolates. A single novel nucleotide polymorphism (SNP) 
in hemA, which encodes a glutamyl- tRNA reductase that catalyses the initial step of porphyrin biosynthesis leading to the 
production of haem, was responsible for the SCV phenotype. We showed the SNP in hemA resulted in a significant fitness cost 
to the isolate, which persisted even in the presence of hemin. However, the phenotype quickly reverted during sequential sub- 
culturing in liquid growth media. As hemA is not found in mammalian cells, and disruption of the gene results in a significant 
fitness cost, it represents a potential target for novel drug development specifically for the treatment of catheter- associated 
urinary tract infections caused by E. coli.
INTRODUCTION
Small colony variants (SCVs) are slower growing mutants 
observed in the study of multiple bacterial species. They have 
altered, smaller than normal, colony morphology, which is 
usually due to mutations within genes involved in metabolic 
processes, for example in genes involved in the electron 
transport chain of Staphylococcus aureus [1]. SCVs have 
been isolated from multiple infection sites, including tissue, 
bone and device- associated infections [2] and can result in 
increased resistance to aminoglycosides [3, 4], which can 
also be used to select for SCVs in vitro [5]. The mechanism 
of decreased susceptibility to aminoglycosides has not been 
extensively investigated but in Staphylococcus aureus and 
Escherichia coli it has been suggested to be due to reduced 
uptake caused by alterations in membrane potential [6, 7]. 
Investigations of SCVs of E. coli are relatively rare but have 
also been associated with mutations within genes encoding 
proteins involved in the electron transport chain, including 
yigP [4], hemB [8] and lipA [9]. SCVs of E. coli have been 
isolated from urinary tract infections [10], bacteraemia [11] 
and chronic hip infections [8] and are therefore increasingly 
considered clinically relevant [12].
An important enzyme involved in the electron transport 
chain is HemA. HemA is a glutamyl- tRNA reductase that 
catalyses the initial step of porphyrin biosynthesis leading 
to the production of haem, which is required for respiration. 
Single nucleotide polymorphisms (SNPs) identified within 
hemA have been found to result in a SCV in several bacterial 
genera, including Salmonella [3, 13] and Listeria [14, 15], 
as well as in E. coli [16]. The morphology of three SCVs of 
Listeria monocytogenes, all with a common SNP present in 
hemA resulting in early termination of the protein, were 
rescued when grown in the presence of exogenous hemin, 
suggesting they were auxotrophic for haem [15].
Here we report the identification of a novel SNP in hemA 
resulting in a SCV phenotype of an amoxicillin/clavulanic 
acid (AMC)- resistant derivative of clinical isolate of E. coli 
from Malawi, which was selected for in vitro in a subinhibi-
tory concentration of gentamicin. We assessed the effect of 
this SNP on the fitness of the SCV compared to the ancestral 
isolates and, as biofilm- producing E. coli are common etio-
logical agents of catheter- associated UTIs [17], we sought to 
determine the biofilm- forming ability of the SCV.
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METHODS
Bacterial strains, media and antibiotics
E. coli 10129 is a susceptible clinical isolate from Malawi 
isolated from cerebral spinal fluid [18] and E. coli 10129 LB_2 
is an in vitro derived isolate with resistance to amoxicillin/
clavulanic acid (AMC) [19]. Both isolates were previously 
whole- genome sequenced and are available in GenBank 
under the following accession numbers: assembly of E. coli 
10129; SIJF00000000 and sequencing reads of E. coli 10129 
LB_2; SAMN10963734.
All bacterial cultures were initially grown on LB (Lennox) 
agar (Sigma, UK) for 18 h at 37 °C then subcultured into 
cation- adjusted Mueller–Hinton Broth (CA- MHB), LB 
(Lennox) broth (LB) (both Sigma, UK) or Iso- sensitest broth 
(ISO, Oxoid, UK) and incubated at 37 °C, 200 r.p.m. for 18 h 
unless otherwise stated.
Gentamicin were solubilized in molecular grade water (all 
Sigma, UK) and filter sterilized through a 0.22 µM polyether-
sulfone filter unit (Millipore, USA).
Selection of gentamicin-resistant colonies
An initial culture of E. coli 10129 LB_2 was diluted 1/1000 in 
LB plus 1 µg ml−1 gentamicin and incubated for 24 h at 37 °C, 
200 r.p.m. Following incubation, the culture was serially 
diluted 1 in 10 to the 10−2 dilution and 50 µl plated out on LB 
agar plus 16 µg ml−1 gentamicin and incubated at 37 °C for 
18 h. A SCV, designated E. coli 10129 LB_2.6 and a normal 
sized colony, designated E. coli 10129 LB_2.5 were immedi-
ately stored at −80 °C.
Antimicrobial susceptibility testing
MIC of gentamicin towards E. coli 10129, E. coli 10129 LB_2 
and E. coli 10129 2.6 were determined using the microdilu-
tion broth method following the CLSI guidelines [20] using 
CA- MHB and performed in triplicate. An additional MIC of 
gentamicin towards E. coli 10129 LB_2.6 was also performed 
in triplicate supplemented with 20 µg ml−1 hemin (Sigma, 
UK).
Characterization of colony and cell morphology
E. coli 10129, E. coli 10129 LB_2, E. coli 10129 LB_2.5 and 
E. coli 10129 LB_2.6 were all grown on LB agar, both with 
and without supplementation of 20 µg ml−1 hemin and 
CHROMagar Orientation agar for 18 h at 37 °C in triplicate 
then photographed under a Celestron MicroDirect 1080 p 
HD Handheld Digital microscope (Celestron, USA). Gram 
stain of each isolate was performed using a standard protocol 
(Sigma, UK) in triplicate and visualized under a Motic Trin-
ocular light microscope mounted with a Moticam X Lite 
camera (Motic, Hong Kong).
Stability of the small-colony phenotype
E. coli 10129, E. coli 10129 LB_2, E. coli 10129 LB_2.5 and 
E. coli 10129 LB_2.6 were grown in 10 ml LB for 18 h at 37 °C, 
200 r.p.m. Following growth, 10 µl was passaged in to fresh 
10 ml LB and incubated at 37 °C, 200 r.p.m. for 24 h and 
repeated for a total of 3 days. Each culture on each day was 
subcultured on to LB agar and incubated for 18 h at 37 °C, the 
colonies on each plate where photographed under a Celestron 
MicroDirect 1080 p HD Handheld Digital microscope.
Whole-genome sequencing and bioinformatics 
analysis
Short- read (2×250 bp paired end) genome sequencing of 
E. coli 10 129 LB_2.6 using the Illumina MiSeq platform, and 
subsequent read trimming, was provided by MicrobesNG 
(http://www. microbesng. uk). The genome was de novo assem-
bled using SPAdes (v3.12.0 [21]) and annotated using Prokka 
(v1.12 [22]). The sequencing reads of E. coli 10 129 LB_2.6 
were aligned to the annotated assembled genomes of E. coli 
10 129 and E. coli 10 129 LB_2 to identify statistically relevant 
SNPs, indels, duplications and amplifications using Breseq 
(v0.32.0 [23]). Protein structure predictions were carried out 
using I- TASSER (https:// zhanglab. ccmb. med. umich. edu/ I- 
TASSER/) [24] and comparisons carried out using Tm- align 
(https:// zhanglab. ccmb. med. umich. edu/ TM- align/) [25]. 
Protein models used in structural comparisons were selected 
based on the highest C- score and TM- score.
DNA extraction
DNA extraction was performed using the PureGene Yeast/
Bact kit B (Qiagen, Germany) following the manufacturer’s 
instructions for extraction of DNA from Gram- negative 
bacteria and eluted in molecular grade water.
PCR
All PCR was performed using 0.02 U/µl Q5 High- Fidelity 
DNA Polymerase (New England Biolabs, USA), 1×Q5 Reac-
tion Buffer, 0.5 µM primers and 200 µM dNTPs in a total 
volume of 25 µl and, unless otherwise stated, all PCR products 
were purified using the Monarch PCR and DNA Clean- up Kit 
(New England Biolabs, USA) following the manufacturer’s 
instructions and eluted in molecular grade water unless stated.
Amplification of 819 bp of hemA was performed the primers 
HemA_F ( TGTCGACGTGTAACCGCACA) and HemA_R, 
( CCAC AGCA GCAG CTTT CCGTTG) and the following 
protocol: denaturation at 98 °C for 30 s, followed by 35 cycles 
of denaturation at 98 °C for 10 s, annealing at 70 °C for 30 s 
and elongation at 72 °C for 50 s, followed by a single, final 
extension of 2 min at 72 °C. The entire 1257 bp of hemA 
from E. coli 10129 was amplified using the primers HA1_F 
( ATGACCCTTTTAGCACTCGG) and HA1_R (CTACTC-
CAGCCCGAGGCT) in a total volume of 50 µl and the 
following protocol: denaturation at 98 °C for 30 s, followed by 
35 cycles of denaturation at 98 °C for 10 s, annealing at 66 °C 
for 30 s and elongation at 72 °C for 13 s, followed by a single, 
final extension step 72 °C for 2 min. A band at approximately 
1 kb was excised and DNA extracted using the Monarch DNA 
Gel Extraction Kit (New England Biolabs, USA) following 
the manufacturer’s instructions. The restriction sites for the 
restriction enzymes KpnI were added to the 5′ ends of the 
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1257 bp double- stranded amplicon by a second round of PCR, 
using the primers KpnIHA_F1 ( AAAAA GGTACC ATGACC-
CTTTTAGCACTCGG) and KpnIHA_R1 ( AAAAA GGTACC 
CTACTCCAGCCCGAGGCT) (KpnI site is underlined). 
Amplification was performed using the same protocol as the 
initial amplification of hemA.
Construction of complement plasmid
The resulting PCR product of the PCR amplifying the wild- 
type hemA with added KpnI sites and the recipient plasmid 
pHSG396 were digested with the restriction enzyme KpnI 
(New England Biolabs, USA). PCR clean- up was then 
performed using the Monarch PCR and DNA Clean- up Kit 
following the manufacturer’s instructions. The digested hemA 
PCR product and pHSG396 were ligated together using T4 
ligase (New England Biolabs, USA), at a 3 : 1 insert to vector 
mass ratio, incubated at room temperature for 10 min followed 
by 65 °C for 10 min.
The ligated, recombinant plasmid (2 µl of the ligation mix) 
was transformed into NEB 5- alpha competent E. coli (New 
England Biolabs, USA) using the following protocol: the reac-
tion was incubated on ice for 30 min, then heat shocked at 
42 °C for 30 s. Following a second incubation on ice for 5 min, 
950 µl of SOC outgrowth medium was added and incubated at 
37 °C, 250 r.p.m. for 1 h. The transformed cells were plated out 
onto LB agar supplemented with 35 µg ml−1 chloramphenicol 
and Isopropyl β-D-1- thiogalactopyranoside (IPTG)/X- gal 
(Fisher Scientific, USA) and incubated at 37 °C for 18 h 
and the plasmid was extracted using the Monarch Plasmid 
Miniprep Kit (New England Biolabs, USA) following the 
manufacturer’s instructions. hemA in pHSG396 was Sanger 
sequenced by GeneWiz (Takely, UK) using commercially 
available M13 primers. E. coli 10129 LB_2.6 was made compe-
tent following the protocol set out in Chung et al. [26] and 
pHSG396 and pHSG396:hemA was transformed following 
the above protocol. E. coli 10129 LB_2.6 with pHSG396 and 
E. coli 10129 LB_2.6 with pHSG396:hemA were both plated 
out on to LB agar supplemented with 35 µg ml−1 chloram-
phenicol and 1 mM IPTG in triplicate and photographed 
under a Celestron MicroDirect 1080 p HD Handheld Digital 
microscope.
Biofilm assay
Biofilm production by E. coli 10129, E. coli 10129 LB_2 and 
E. coli 10129 LB_2.6 was quantified as described previously 
[19]. Briefly, each isolate was initially grown in 10 ml LB, 
then diluted 1/1000 in M9 [50 % (v/v) M9 minimal salts (2×) 
(Gibco, ThermoFisher Scientific, USA), 0.4 % d- glucose, 
4 mM magnesium sulphate (both Sigma, UK) and 0.05 mM 
calcium chloride (Millipore, USA)] with and without supple-
mentation with 20 µg ml−1 hemin. Four technical replicates of 
each diluted culture were added to a 96- well plate and incu-
bated statically for 18 h at 37 °C. Following incubation, each 
well was washed with PBS, stained with 0.1 % crystal violet 
and washed again with PBS. The stain was liberated from the 
96- well plate with 30 % acetic acid (Fisher Scientific, USA) and 
measured at an OD550. Three biological replicates of this assay 
were performed. Biofilm production of E. coli 10129 LB_2.6 
with pHSG396 and E. coli 10129 LB_2.6 with pHSG396:hemA 
was performed as above, except using M9 supplemented with 
35 µg ml−1 chloramphenicol and 1 mM IPTG.
Competitive and comparative fitness assays
Competitive fitness of E. coli 10129 LB_2.6 was assessed 
compared to E. coli 10129 and E. coli 10 129 LB_2 in LB and M9 
as described previously [19]. Briefly, each culture was diluted to 
an OD600 of 0.1 and then diluted 1/1000 and combined 1 : 1 in 
the appropriate media and 150 µl added to a 96- well plate and 
incubated at 37 °C, 200 r.p.m. for 18 h. Bacterial density of the 
initial combined culture and after 24 h incubation was enumer-
ated by diluting the culture in PBS and 50 µl of each dilution 
plated out on LB agar and LB agar plus 20 µg ml−1 gentamicin 
and incubated at 37 °C for 18 h. The Malthusian equation was 
used to calculate competitive relative fitness [27]:
 M = Mm
(
T24
T0
)
/Mwt
(
T24
T0
)
 
W = (M−1)×100,
where W represents relative fitness, M represents the Malthu-
sian parameter, Mwt represents the Malthusian parameter of 
the ancestor isolate, Mm represents the Malthusian parameter 
of the resistant isolate, T0 represents log c.f.u. ml−1 count of 
the initial culture and T24 represents the log c.f.u. ml−1 count 
after 24 h.
Fitness of E. coli 10129 LB_2.6 with pHSG396:hemA was 
compared to E. coli 10129 LB_2.6 with pHSG396 comparatively. 
Each culture was diluted to an OD600 of 0.1 then further diluted 
1/1000 in LB supplemented with 35 µg ml−1 chloramphenicol 
and 1 mM IPTG. Of each diluted culture, 150 µl was added to 
a 96- well plate in duplicate. As a negative control, 150 µl LB 
with 35 µg ml−1 chloramphenicol and 1 mM IPTG was also 
added to the plate in duplicate. All samples were incubated at 
37 °C for 24 h, orbital shaking at 200 r.p.m., in a Clariostar Plus 
microplate reader (BMG Labtech, Germany) measuring the 
OD600 every 10 min. Relative fitness of E. coli 10129 LB_2.6 with 
pHSG396:hemA was compared to E. coli 10129 LB_2.6 with 
pHSG396 using BAT v2.1 [28] with absorbance values between 
0.02 and 0.2 and a minimum R value of 0.9902. Both fitness 
assays were performed in triplicate.
Statistical analysis
Statistical analysis of the competitive fitness and biofilm assays 
were performed using the ordinary one- way ANOVA plus 
uncorrected Fisher’s LSD test and statistical analysis of compara-
tive fitness and biofilm assay of the complemented E. coli 10129 
LB_2.6 isolate was performed using the unpaired t- test (two- 
tailed), all in GraphPad Prism (v8.4.0).
RESULTS
Selection and isolation of a small-colony variant
In a previous study, AMC- resistant derivatives of the clinical 
isolate E. coli 10129 were selected for in vitro in LB in the 
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presence of a sub- inhibitory concentration of AMC [19]. One 
such derivative, E. coli 1029 LB_2, showed high- level resist-
ance to AMC and was found to contain a SNP in the promoter 
region of AmpC [19]. In this study, we selected for gentamicin- 
resistant derivatives of E. coli 10129 LB_2 in vitro via growth in 
the presence of a sub- inhibitory concentration of gentamicin 
in LB, during which we identified a small, pinprick colony 
on the agar plate, which was immediately stored at −80 °C 
and designated E. coli 10129 LB_2.6. Subsequent regrowth of 
E. coli 10129 LB_2.6 confirmed the SCV morphology persisted 
when compared to the two ancestral strains (E. coli 10129 and 
LB_2) and another normal sized isolate, E. coli 10129 LB_2.5, 
from the same selective plate (Fig. 1a). The SCV was confirmed 
to be Gram- negative, however the cell size and shape was not 
observed to be different than that of the two ancestral isolates 
or the E. coli 10129 LB_2.5 strain (Fig. 1d). To ensure that the 
SCV was not a Gram- negative contaminant, we confirmed it 
was E. coli through growth on CHROMagar Orientation agar 
(Fig. 1b). The MIC for gentamicin for E. coli 10129 LB_2.6 and 
E. coli 10129 LB_2.5 was 8 µg ml−1 compared to 1–2 µg ml−1 for 
E. coli 10129 and 2–4 µg ml−1 E. coli 10129 LB_2.
Mutations identified within the genome of E. coli 
10129 LB_2.6
By comparing the whole- genome sequence of the E. coli 10129 
LB_2.6 to the ancestral isolates E. coli 10129 and E. coli 10129 
LB_2, we identified a single novel SNP present in hemA in 
E. coli 10129 LB_2.6 (T>G at hemA nucleotide 426 out of 1257). 
The SNP was predicted to result in a non- synonymous mutation 
leading to a change of phenylalanine to leucine atHemA amino 
acid position 142. This was confirmed to be present in E. coli 
10129 LB_2.6 but absent in E. coli 10129, E. coli 10129 LB_2 and 
E. coli 10129 LB_2.5 by PCR and Sanger sequencing of hemA in 
all four isolates (Fig. S7).
Structural changes are predicted in the HemA from 
the SCV compared to the wild-type
The phenylalanine to leucine change at amino acid 142 is 
predicted to be within an α-helix that links two globular 
domains within the tertiary structure of the proteins, the rela-
tive positions of which are predicted to change (Fig. 2). This is 
predicted to change the position of the substrate binding sites 
for both NAD and glutamyl- tRNA, as determined by Tm- align.
Confirmation of the role of hemA in the small-
colony-variant phenotype
As HemA is involved in the biosynthetic pathway of haem, we 
hypothesized that E. coli 10129 LB_2.6 would be auxotrophic 
for haem due to the mutation in hemA. Therefore, we supplied 
hemin exogenously during growth on agar. We found that 
there was a reversion of the SCV phenotype to normal size of 
the E. coli 10129 and E. coli 10129 LB_2, therefore this muta-
tion is likely to be the cause of the SCV phenotype (Fig. 1c). 
Fig. 1. Photographs of the colonies of (1) E. coli 10129, (2) E. coli 10129 LB_2, (3) E. coli 10129 LB_2.5 and (4) E. coli 10129 LB_2.6 (SCV) 
grown on (a) LB agar, (b) CHROMagar Orientation agar, (c) LB agar plus 20 µg ml−1 hemin (lines on scale are 1 mm increments) and (d) 
Gram stain of each of the isolates (100x magnification). Each photograph is a representative image of three independent replicates (Fig 
S1 and S2).
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Supplementation of 20 µg ml−1 hemin also decreased the 
MIC of gentamicin for E. coli 10 129 LB_2.6 from 8 µg ml−1 
to 4 µg ml−1; comparable to that of the ancestor isolate E. coli 
10129 LB_2 (2–4 µg ml−1), suggesting the SNP in hemA is also 
involved in the susceptibility to gentamicin. To confirm this, 
we rescued the SCV phenotype by transforming a plasmid 
(pHSG396) with and without the cloned hemA from E. coli 
10129 into E. coli 10129 LB_2.6. Using IPTG to induce expres-
sion of hemA in pHSG396, we found a reversion to a ‘normal’ 
colony size in E. coli 10129 LB_2.6::pHSG396:hemA, while 
E. coli 10129 LB_2.6::pHSG396 did not (Fig. 3, S3 and S4), 
therefore the SNP at position amino acid position 142 in 
hemA was confirmed to be responsible for a SCV phenotype 
in E. coli.
Stability of the small-colony-variant phenotype
We sought to determine whether E. coli 10129 LB_2.6 
could revert back to a ‘normal’ sized colony after multiple 
generations. We found that the SCV phenotype returned to 
‘normal’ sized colony phenotype after a small number (1–3) 
of overnight passages and therefore the SCV phenotype was 
not stable (Figs 4, S5 and S6).
Fitness cost of the SNP in hemA
The effect of the mutation and subsequent SCV phenotype 
on fitness compared to the two ancestral isolates E. coli 10129 
and E. coli 10129 LB_2 was assessed competitively. We found 
that E. coli 10129 LB_2.6 carried a significant fitness cost in 
both LB and ISO compared to E. coli 10129 (LB; P- value = 
<0.0001, ISO; P- value=0.0026) and E. coli 10129 LB_2 (LB; P- 
value = <0.0001, ISO; P-value=0.0003) and, despite reversion 
to a ‘normal’ sized colony on LB agar with hemin, the fitness 
cost imposed on E. coli 10129 LB_2.6 compared to E. coli 
10 129 (LB; P- value=0.0787, ISO; P- value=0.3727) and E. coli 
10129 LB_2 (LB; P- value=0.0784, ISO; P- value=0.2317) did 
not show a statistically significant difference when exogenous 
hemin was available (Fig. 5a; F statistic 3.539). To confirm that 
the SNP in hemA was responsible for this observed fitness 
cost, we measured the growth rate of both E. coli 10129 
LB_2.6 containing pHSG396:hemA, induced by IPTG, and 
E. coli 10 129 LB_2.6 containing the empty pHSG396 plasmid 
in LB plus ITPG and chloramphenicol. We then calculated the 
relative fitness by comparing the growth rate of E. coli 10129 
LB_2.6 with pHSG396 to itself, which therefore has a relative 
fitness of 1, and to E. coli 10129 LB_2.6 with pHSG396:hemA. 
Here, we found the expression of the wild- type hemA present 
in pHSG396 increased the relative fitness of E. coli 10129 
LB_2.6 significantly to 1.709 (P- value=0.0422) compared to 
the pHSG396 without hemA (Fig. 5b). Therefore, the SNP in 
hemA was responsible for the significant fitness cost seen in 
E. coli 10129 LB_2.6.
Biofilm production of E. coli 10129 LB_2.6
Biofilm production was significantly impaired in E. coli 10129 
LB_2.6 compared to the immediate ancestor E. coli 10129 
LB_2 (P- value=0.0189) when assessed in M9. However, 
when biofilm production was assessed in M9 supplemented 
with hemin none of the isolates produced a biofilm (Fig. 6a). 
Comparison of biofilm production of E. coli 10129 LB_2.6 
containing pHSG396 to E. coli 10129 LB_2.6 contain 
pHSG396:hemA, we found both produced very little biofilm 
production and no significant difference between the two 
isolates.
DISCUSSION
Previous studies have found that SCVs of different bacterial 
genera have either been developed following selection in, or 
show resistance to, aminoglycosides [3–5] and in this study 
we have identified a novel SNP in hemA in an isolate of E. coli, 
which has resulted in a SCV phenotype following selection 
in gentamicin. The uptake of aminoglycosides is dependent 
on the membrane potential and often requires respiration. 
Previously, Lazar et al. linked a SNP in hemA with resistance 
to aminoglycosides due to disruption of the respiratory trans-
port chain, subsequently altering the membrane potential, 
Fig. 2. Structural alignment of WT (blue) and SCV (red) HemA. The 
changed amino acid at position 142 is indicated within an α-helix. The 
differential predicted position of the tertiary structure of the HemA is 
indicated with brackets.
Fig. 3. Photographs of the colonies of E. coli 10129 LB_2.6 transformed 
with (a) pHSG396:hemA and (b) pHSG396. Each photograph is a 
representative image of three independent replicates (Fig S3 and S4). 
Lines on scale are 1 mm increments.
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Fig. 4. Photographs of the colonies of (a) E. coli 10129, (b) E. coli 10129 LB_2 and (c) E. coli 10129 LB_2.5 and (d) E. coli 10129 LB_2.6 
grown on LB agar after 1, 2 and 3 passages. Each photograph is a representative image of three independent replicates (Fig S5 and S6). 
Lines on scale are 1 mm increments.
Fig. 5. (a) Relative fitness of E. coli 10129 LB_2.6 (SCV) to the immediate ancestor E. coli 10129 LB_2 and E. coli 10129 in ISO and LB, 
with and without addition of 20 µg ml−1 hemin assessed competitively. (b) Relative fitness of E. coli 10129 LB_2.6 with pHSG396:hemA 
compared to E. coli 10 129 LB_2.6 with pHSG396, assessed comparatively.
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in E. coli [7]. In this study we found that the addition of 
exogenous hemin reduced the gentamicin MIC of the SCV 
comparable to that of the ancestor isolate, E. coli 10129 LB_2, 
suggesting that the novel SNP in hemA influences resistance 
to gentamicin. Previous SNPs in hemA resulting in the SCV 
phenotype have been identified, which resulted in amino 
acid changes at position valine-45- glycine [3, 13], serine-
232- stop [3, 13] and glutamine-225- stop [14, 15], with the 
latter two resulting in an early termination of the protein. 
The SNP we identified in this E. coli isolate resulted in an 
amino acid substitution at position 142 and did not lead to 
a premature stop. Mutations in hem genes often result in the 
SCV becoming auxotrophic for hemin [15, 29, 30], and the 
SNP we identified in hemA was confirmed to result in a haem 
auxotroph phenotype, which also carried a significant fitness 
cost, which persists even in the presence of exogenous hemin.
Sequential subculture in liquid media showed that the SCV 
reverted to wild- type colony phenotype with 1–3 of the 
subcultures suggesting that compensatory mutations are 
likely occurring resulting in a fitness benefit compared to 
the SCV. As the SCV is so unfit compared to the ancestral 
strain any compensatory mutation resulting in even a modest 
improvement in fitness would quickly be selected in our assay 
and this can explain the variation in the colony sizes and time 
of emergence between the replicate evolution experiments 
(Figs 4, S5 and S6).
The SCV also has impaired biofilm formation compared to 
the ancestral isolates, which again did not alter in the pres-
ence of exogenous hemin. However, in the presence of hemin, 
all isolates tested in this study were unable to form biofilms. 
Therefore, while our results indicate that the SNP in hemA 
may affect biofilm formation in the absence of hemin it 
appears that hemin itself may also interfere with E. coli biofilm 
formation, as has been previously shown for Porphyromonas 
gingivalis [31]. Attempts to determine the biofilm- forming 
capability of a complemented strain, plus a strain carrying 
only the expression plasmid, resulted in little or no biofilm 
being formed. Recently the effect of IPTG, which is used to 
induce production of HemA in our complemented strains, 
has been shown to negatively affect plasmid stability in, and 
viability of, planktonically growing E. coli cells [32]. This 
makes interpretation of our data difficult as the transition 
from planktonic to biofilm- growing cells is exactly when we 
need to induce expression of hemA with IPTG to determine 
its effect on biofilm formation in our complemented strains. 
Further work will be aimed at determining if complemen-
tation will result in wild- type biofilm formation using an 
alternative expression system.
Even though HemA is non- essential for growth, it has been 
identified as a potential drug target against Acinetobacter 
baumannii as it is not present in mammalian cells [33]. As 
the mutation in hemA significantly affects the fitness and 
biofilm production of this E. coli isolate, HemA may have 
target potential for novel compounds, which could reduce 
fitness of E. coli, leading to them being outcompeted by a 
resident microbiome, and reduced biofilm formation, which, 
for E. coli, are a common cause of catheter- associated UTIs 
[17].
Conclusions
A novel SNP in hemA that emerged upon in vitro, sub- 
inhibitory gentamicin selection of a clinical isolate of E. coli 
results in a SCV phenotype, which is auxotrophic for haem 
and carries a significant fitness cost even in the presence of 
exogenous hemin, The SCV also has significantly impaired 
biofilm production relative to the ancestral isolate, opening 
up therapeutic possibilities with the development of hemA 
inhibitors.
Fig. 6. Biofilm production of (a) E. coli 10129, E. coli 10129 LB_2 and E. coli 10129 LB_2.6 (SCV) in M9 and M9 supplemented with 20 µg ml−1 
hemin and (b) E. coli 10129 LB_2.6 containing pHSG396 or pHSG396:hemA.
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